select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Myocardial Ischemia-Pipeline Review, H2 2016

Myocardial Ischemia-Pipeline Review, H2 2016


  • Products Id :- GMDHC8431IDB
  • |
  • Pages: 84
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Myocardial Ischemia-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Myocardial Ischemia-Pipeline Review, H2 2016', provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia

The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects

The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Myocardial Ischemia Overview 8

Therapeutics Development 9

Pipeline Products for Myocardial Ischemia-Overview 9

Pipeline Products for Myocardial Ischemia-Comparative Analysis 10

Myocardial Ischemia-Therapeutics under Development by Companies 11

Myocardial Ischemia-Therapeutics under Investigation by Universities/Institutes 12

Myocardial Ischemia-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Myocardial Ischemia-Products under Development by Companies 16

Myocardial Ischemia-Products under Investigation by Universities/Institutes 17

Myocardial Ischemia-Companies Involved in Therapeutics Development 18

Bayer AG 18

Cellmid Limited 19

CohBar, Inc. 20

Lixte Biotechnology Holdings, Inc. 21

Miltenyi Biotec GmbH 22

NoNO, Inc. 23

Shire Plc 24

Symic Biomedical, Inc. 25

Taxus Cardium Pharmaceuticals Group Inc. 26

ViroMed Co., Ltd. 27

Myocardial Ischemia-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

AB-002-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Alda-1-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

alferminogene tadenovec-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AntimiR-199a-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BAY-606583-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CMK-103-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

EP-80317-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Humanin-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

LB-100-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Peptagon-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

PMC-6-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

SB-030-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Inhibit Mst1 for Myocardial Ischemia-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Stem Cell Therapy for Cardiovascular Disease-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

VM-202-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Myocardial Ischemia-Dormant Projects 68

Myocardial Ischemia-Discontinued Products 69

Myocardial Ischemia-Product Development Milestones 70

Featured News & Press Releases 70

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 70

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 71

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 72

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 72

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 73

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 73

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 74

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 76

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 78

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 78

Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition 79

Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 80

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 82

Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Figures

Number of Products under Development for Myocardial Ischemia, H2 2016 9

Number of Products under Development for Myocardial Ischemia-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Top 10 Targets, H2 2016 29

Number of Products by Stage and Top 10 Targets, H2 2016 29

Number of Products by Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

List of Tables

Number of Products under Development for Myocardial Ischemia, H2 2016 9

Number of Products under Development for Myocardial Ischemia-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Myocardial Ischemia-Pipeline by Bayer AG, H2 2016 18

Myocardial Ischemia-Pipeline by Cellmid Limited, H2 2016 19

Myocardial Ischemia-Pipeline by CohBar, Inc., H2 2016 20

Myocardial Ischemia-Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 21

Myocardial Ischemia-Pipeline by Miltenyi Biotec GmbH, H2 2016 22

Myocardial Ischemia-Pipeline by NoNO, Inc., H2 2016 23

Myocardial Ischemia-Pipeline by Shire Plc, H2 2016 24

Myocardial Ischemia-Pipeline by Symic Biomedical, Inc., H2 2016 25

Myocardial Ischemia-Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016 26

Myocardial Ischemia-Pipeline by ViroMed Co., Ltd., H2 2016 27

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Myocardial Ischemia-Dormant Projects, H2 2016 68

Myocardial Ischemia-Discontinued Products, H2 2016 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Cellmid Limited

CohBar, Inc.

Lixte Biotechnology Holdings, Inc.

Miltenyi Biotec GmbH

NoNO, Inc.

Shire Plc

Symic Biomedical, Inc.

Taxus Cardium Pharmaceuticals Group Inc.

ViroMed Co., Ltd.

Myocardial Ischemia Therapeutic Products under Development, Key Players in Myocardial Ischemia Therapeutics, Myocardial Ischemia Pipeline Overview, Myocardial Ischemia Pipeline, Myocardial Ischemia Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com